102,448 Shares in Immuneering Corporation $IMRX Acquired by Hudson Bay Capital Management LP

Hudson Bay Capital Management LP bought a new stake in Immuneering Corporation (NASDAQ:IMRX) during the third quarter, Holdings Channel.com reports. The firm bought 102,448 shares of the company’s stock, valued at approximately $717,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Jane Street Group LLC bought a new stake in shares of Immuneering in the 1st quarter valued at about $32,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Immuneering in the 3rd quarter valued at about $35,000. Future Financial Wealth Managment LLC bought a new stake in shares of Immuneering during the third quarter valued at approximately $35,000. Kingsview Wealth Management LLC acquired a new position in Immuneering during the second quarter worth $47,000. Finally, Mercer Global Advisors Inc. ADV bought a new position in Immuneering in the 3rd quarter valued at about $70,000. 67.65% of the stock is owned by institutional investors.

Insider Buying and Selling at Immuneering

In other news, Director Peter Feinberg acquired 20,000 shares of Immuneering stock in a transaction that occurred on Monday, January 12th. The shares were bought at an average cost of $4.35 per share, with a total value of $87,000.00. Following the transaction, the director directly owned 135,441 shares of the company’s stock, valued at $589,168.35. This trade represents a 17.32% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Thomas J. Schall acquired 21,645 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The shares were bought at an average price of $4.67 per share, with a total value of $101,082.15. Following the acquisition, the director directly owned 74,530 shares in the company, valued at $348,055.10. This represents a 40.93% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 51,819 shares of company stock worth $234,472 in the last 90 days. 22.90% of the stock is currently owned by company insiders.

Immuneering Price Performance

Shares of IMRX stock opened at $5.02 on Monday. Immuneering Corporation has a 1 year low of $1.10 and a 1 year high of $10.08. The company has a market cap of $324.54 million, a price-to-earnings ratio of -3.64 and a beta of 0.46. The firm has a fifty day moving average price of $4.97 and a 200-day moving average price of $6.10.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings results on Friday, March 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.13. Equities research analysts expect that Immuneering Corporation will post -1.86 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Wall Street Zen raised Immuneering from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of Immuneering in a report on Monday, March 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Immuneering currently has an average rating of “Moderate Buy” and a consensus target price of $16.50.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.